Zenotech posts ₹0.46 Cr Q1 FY27 loss, reversing YoY profit; loss narrows 86% QoQ
PAT -146.03% YoY · revenue +11.08% · margins compressing
₹9.6 Cr
+11.08% YoY
₹-0.46 Cr
-146.03% YoY
-4.12%
-13.8pp YoY
₹-0.07
Zenotech Laboratories, reporting standalone-only figures (it has no subsidiaries, JVs or associates under Ind AS 110 — its overseas units are defunct or wound up), posted revenue from operations of ₹9.60 Cr in Q1 FY27, up 11.1% YoY from ₹8.64 Cr and 8.3% QoQ from ₹8.87 Cr in Q4 FY26. Despite the topline growth, the company swung to a net loss of ₹0.46 Cr (basic EPS -₹0.07) against a profit of ₹0.99 Cr (EPS ₹0.16) in the year-ago quarter — the primary YoY signal is a reversal from profit to loss, not the revenue gain. Sequentially the loss narrowed sharply, down 86% from Q4 FY26's ₹3.15 Cr loss.
Q1 FY-2027 vs prior quarters
The YoY swing was driven by cost growth outrunning revenue: employee benefit expense rose 39% YoY to ₹4.92 Cr (₹3.54 Cr) and other expenses rose 32% YoY to ₹4.83 Cr (₹3.65 Cr), lifting total expenses 30% YoY to ₹11.65 Cr against just 11% revenue growth. Net margin (PAT/total income) compressed to -4.1% from +9.7% a year ago, though it improved from -30.1% in Q4 FY26 — Q4's deeper loss was itself inflated by a one-off ₹2.39 Cr prior-period tax charge not repeated this quarter. This quarter carried no exceptional item (Q4 FY26 had a ₹0.05 Cr exceptional gain), and a ₹0.15 Cr net deferred-tax credit narrowed the pretax loss of ₹0.60 Cr to the ₹0.46 Cr net loss.
The stock went into the print at ₹45, up 0.9% over the past month of trading.
There is no management guidance on record from prior quarters and none disclosed in this filing, so the print cannot be graded against a stated outlook; a web search found no analyst previews or consensus estimates for this stock either, consistent with it being a micro-cap with negligible coverage. The filing itself contains no separate press release or management commentary beyond the regulatory outcome letter and standard notes — there is no company framing of the quarter to reconcile against the numbers. The only corporate development in the window was procedural: the July 13, 2026 board-meeting intimation and the June 30 trading-window closure ahead of this result, plus the now-approved 37th AGM (September 25, 2026); none bear directly on the operating numbers.
W1
Whether 11% YoY revenue growth can outpace cost inflation — employee costs rose 39% YoY this quarter — to return the company to profit.
W2
Continuation of the sequential loss-narrowing trend (₹3.15 Cr to ₹0.46 Cr over two quarters) in the next print.
W3
Sustainability of the ₹0.15 Cr deferred-tax credit that cushioned this quarter's bottom line; its absence would widen the loss.